Objective: The aim of this study was to examine the utilization of mammography and bone mineral density (BMD) screenings and factors associated with compliance according to the recommended clinical practice guidelines.
Methods: Mammography and BMD were assessed using employer's administrative claims data for eligible women identified between January 2004 and December 2006. Women were categorized into five cohorts based on mammography- and BMD-recommended screening guidelines. Logistic regression modeling was used to examine the covariates associated with compliance.
Results: Mammography and BMD screening utilization were low in relation to recommendations, with 21%, 27%, and 16% of women complying with mammography, age-motivated BMD, and fracture-motivated BMD screening guidelines, respectively. BMD screening use (odds ratio [OR], 7.19; 95% CI, 7.08-7.31) was associated with compliance in the mammogram cohort. Mammogram use was associated with compliance in both the age-motivated BMD cohort (OR, 6.01; 95% CI, 5.28-6.85) and the fracture-motivated BMD cohort (OR, 2.20; 95% CI, 2.07-2.33). Having a Papanicolaou test was strongly associated with compliance in the combined mammogram plus age-motivated BMD cohort (OR, 16.83; 95% CI, 14.01-20.22) and the combined mammogram plus fracture-motivated BMD cohort (OR, 10.46; 95% CI 9.26-11.81).
Conclusions: Postmenopausal women with employer-sponsored health insurance had low utilization of mammography and BMD screening relative to clinical guidelines. Use of other health screening services was associated with compliance with guidelines. Methods to improve adherence to mammography and BMD screening guidelines should be explored, which could possibly leverage the increased likelihood that women who receive one screening service will receive another.
Women at least 50 years of age with employer-sponsored health insurance had low utilization of mammography and bone mineral density screening relative to clinical guidelines. Women who received other screening services were more likely to be compliant with mammography and bone mineral density guidelines.
From the 1Eli Lilly and Company, Indianapolis, IN; and 2ZS Associates, New York, NY.
Received September 29, 2010; revised and accepted November 23, 2010.
Funding/source: This study was funded by Eli Lilly and Company, Indianapolis, IN.
Financial disclosure/conflicts of interest: E.S.M., B.D.M., and J.L.M. are employees of Eli Lilly and Company and hold stock and stock options. A.W., N.McQ., and N.G. are employees of ZS Associates and were paid collaborators of Eli Lilly and Company.
Address correspondence to: Eric S. Meadows, PhD, Eli Lilly and Company, Global Health Outcomes, Indianapolis, IN 46285. E-mail: email@example.com